



Reena Thomas

Clinical Assistant Professor, Neurology & Neurological Sciences

CLINICAL OFFICES

- **Stanford Cancer Center Neuro Oncology**

875 Blake Wilbur Dr Rm CC2221

Stanford, CA 94305

Tel (650) 498-6000

Fax (650) 724-3556

ACADEMIC CONTACT INFORMATION

- **Administrative Contact**

Tel (650) 725-8630

Bio

BIO

Dr. Reena Thomas received her medical degree from Georgetown University School of Medicine in Washington, DC and her PhD from the City of Hope Graduate School in Duarte, California. She completed her training as a resident in Neurology as well as her fellowship training in Neuro-Oncology at Stanford University Hospital. Her research background and interests are focused on immune based cancer therapies and chemokine signaling in glioblastoma brain tumors. She has also been involved in advanced imaging studies of glioblastoma. She is the Director of the Adult Neuro Oncology Fellowship at Stanford.

CLINICAL FOCUS

- Neuro Oncology
- Fellowship Program Director
- Neurology
- Immunotherapy
- Immuno Oncology
- Primary Brain Tumors
- Metastatic Cancer to CNS

ACADEMIC APPOINTMENTS

- Clinical Assistant Professor, Neurology & Neurological Sciences
- Member, Stanford Cancer Institute

ADMINISTRATIVE APPOINTMENTS

- Adult Neuro Oncology Fellowship Program Director, Stanford Hospital, (2014- present)
- Director of Diversity and Inclusion, Department of Neurology, (2017- present)
- Education Chief of Neuro Oncology, Department of Neurology, (2017- present)

HONORS AND AWARDS

- Mentor of the Year, 1st Gen Mentorship Program, Stanford School of Medicine (November 2018)

- Graduating Resident Teaching Award, Stanford Neurology (July 2013)
- Silicon Valley Top 40 under 40, Silicon Valley Business Journal (December 2014)
- Principal Investigator of SPARK Grant, Stanford University (2015-2018)
- Stanford Faculty Development Grant, Hispanic Center of Excellence (2015, 2018)

BOARDS, ADVISORY COMMITTEES, PROFESSIONAL ORGANIZATIONS

- Member, American Academy of Neurology (2010 - present)
- Member, Society for Neuro Oncology (2011 - present)
- Member, Stanford Society of Physician Scholars (2011 - present)
- Board Certified, American Board of Psychiatry and Neurology (2014 - present)
- Member, American Society of Clinical Oncology (2015 - present)

PROFESSIONAL EDUCATION

- BA, Cornell University , Biology; Neurobiology and Behavior (2002)
- PhD, City of Hope Graduate School of Biological Sciences, City of Hope Cancer Center , Molecular Immunology (2006)
- Medical Education: Georgetown University School of Medicine (2009) DC
- Internship: Georgetown University School of Medicine Registrar (2010) DC
- Residency: Stanford University School of Medicine (2013) CA
- Board Certification: Neurology, American Board of Psychiatry and Neurology (2014)
- Fellowship: Stanford University School of Medicine (2014) CA

COMMUNITY AND INTERNATIONAL WORK

- Faculty Mentor
- Board Member

LINKS

- Get a Second Opinion: <https://stanfordhealthcare.org/second-opinion/overview.html>

Research & Scholarship

CLINICAL TRIALS

- [18F]DASA-23 and PET Scan in Evaluating Pyruvate Kinase M2 Expression in Patients With Intracranial Tumors or Recurrent Glioblastoma and Healthy Volunteers, Recruiting
- Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery, Recruiting
- A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM), Not Recruiting
- A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE), Not Recruiting
- An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by Itself, Not Recruiting
- BPM31510 in Treating Patients With Recurrent High-Grade Glioma Previously Treated With Bevacizumab, Not Recruiting
- Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Detecting Lactate and Bicarbonate in Participants With Central Nervous System Tumors, Not Recruiting
- INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM), Not Recruiting
- Memantine Hydrochloride and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients With Brain Metastases, Not Recruiting
- Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma, Not Recruiting

- Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies, Not Recruiting
- The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma, Not Recruiting

Teaching

GRADUATE AND FELLOWSHIP PROGRAM AFFILIATIONS

- Oncology (Fellowship Program)

Publications

PUBLICATIONS

- **Rooting out racial stereotypes in Neurology (R) A commentary on "Lucky and the root doctor"** *NEUROLOGY*
Hamilton, R. H., McClean, J. C., Greicius, M. D., Gamaldo, C. E., Burrus, T. M., Charleston, L., Correa, D. J., Ebong, I. M., Hamilton, R., Lewis, S., Thomas, R. P., Vargas, A., Flippen, et al
2019; 92 (22): 1029–32
- **Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (CheckMate 204).**
Tawbi, H., Forsyth, P. J., Hodi, F., Lao, C. D., Moschos, S. J., Hamid, O., Atkins, M. B., Lewis, K. D., Thomas, R., Glaspy, J. A., Jang, S., Algazi, A., Khushalani, et al
AMER SOC CLINICAL ONCOLOGY.2019
- **Rooting out racial stereotypes in Neurology: A commentary on "Lucky and the root doctor".** *Neurology*
Hamilton, R. H., McClean, J. C., Greicius, M. D., Gamaldo, C. E., Burrus, T. M., Charleston, L. 4., Correa, D. J., Ebong, I. M., Hamilton, R., Lewis, S., Thomas, R. P., Vargas, A., Flippen, et al
2019
- **Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities** *PIGMENT CELL & MELANOMA RESEARCH*
Eroglu, Z., Holmen, S. L., Chen, Q., Khushalani, N. I., Amaravadi, R., Thomas, R., Ahmed, K. A., Tawbi, H., Chandra, S., Markowitz, J., Smalley, I., Liu, J. C., Chen, et al
2019; 32 (3): 458–69
- **EEG Findings in Chimeric Antigen Receptor T-Cell (CAR-T) Related Encephalopathy Syndrome**
Satyanarayan, S., Markert, M., Hovsepian, D., Post, D., Muffly, L., Miklos, D., Thomas, R., Scott, B.
LIPPINCOTT WILLIAMS & WILKINS.2019
- **Neurological Adverse Effects Due to Programmed Death (PD-1) Inhibitors**
Shi, S., Kanwar, R., Varanasi, V., Eisinger, E., Thomas, R., Moore, J.
LIPPINCOTT WILLIAMS & WILKINS.2019
- **Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities.** *Pigment cell & melanoma research*
Eroglu, Z., Holmen, S. L., Chen, Q., Khushalani, N. I., Amaravadi, R., Thomas, R., Ahmed, K. A., Tawbi, H., Chandra, S., Markowitz, J., Smalley, I., Liu, J. K., Ann Chen, et al
2019
- **Macrophage Exclusion after Radiation Therapy (MERT): A First in Human Phase I/II Trial using a CXCR4 Inhibitor in Glioblastoma.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
Thomas, R. P., Nagpal, S., Iv, M., Soltys, S. G., Bertrand, S., Pelpola, J. S., Ball, R. L., Yang, J., Sundaram, V., Lavezo, J. L., Born, D. E., Vogel, H., Brown, et al
2019
- **Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.** *The New England journal of medicine*
Tawbi, H. A., Forsyth, P. A., Algazi, A., Hamid, O., Hodi, F. S., Moschos, S. J., Khushalani, N. I., Lewis, K., Lao, C. D., Postow, M. A., Atkins, M. B., Ernstoff, M. S., Reardon, et al
2018; 379 (8): 722–30
- **Quantification of Macrophages in High-Grade Gliomas by Using Ferumoxytol-enhanced MRI: A Pilot Study.** *Radiology*
Iv, M., Samghabadi, P., Holdsworth, S., Gentles, A., Rezaii, P., Harsh, G., Li, G., Thomas, R., Moseley, M., Daldrup-Link, H. E., Vogel, H., Wintermark, M., Cheshier, et al

2018: 181204

- **Conditional Probability of Survival as a Proposed Endpoint for Future Single-Arm Clinical Trials in Glioblastoma**
Patel, C. B., Thomas, R. P., Nagpal, S., Recht, L. D.
WILEY.2017: S206–S207
- **Anti-PD-1-associated inflammatory-demyelinating lesions in patients with brain metastases**
Samghabadi, P., Makar, S., Thomas, R., Pelpola, J., Reddy, S., Tranvinh, E., Spence, A., Vogel, H., Born, D., Sobel, R.
OXFORD UNIV PRESS INC.2017: 500–501
- **Phase 1/2 Trial of 5-Fraction Stereotactic Radiosurgery With 5-mm Margins With Concurrent and Adjuvant Temozolomide in Newly Diagnosed Supratentorial Glioblastoma: Health-Related Quality of Life Results.** *International journal of radiation oncology, biology, physics*
Pollom, E. L., Fujimoto, D., Wynne, J., Seiger, K., Modlin, L. A., Jacobs, L. R., Azoulay, M., von Eyben, R., Tupper, L., Gibbs, I. C., Hancock, S. L., Li, G., Chang, et al
2017; 98 (1): 123-130
- **Melanoma central nervous system metastases: current approaches, challenges, and opportunities** *PIGMENT CELL & MELANOMA RESEARCH*
Cohen, J. V., Tawbi, H., Margolin, K. A., Amravadi, R., Bosenberg, M., Brastianos, P. K., Chiang, V. L., de Groot, J., Glitza, I. C., Herlyn, M., Holmen, S. L., Jilaveanu, L. B., Lassman, et al
2016; 29 (6): 627-642
- **Response of metastatic glioma to vemurafenib.** *Neuro-oncology practice*
Leaver, K. E., Zhang, N., Ziskin, J. L., Vogel, H., Recht, L., Thomas, R. P.
2016; 3 (4): 268–71
- **Phase II pilot study of single-agent etirinotecan pegol (NKTR-102) in bevacizumab-resistant high grade glioma** *JOURNAL OF NEURO-ONCOLOGY*
Nagpal, S., Recht, C. K., Bertrand, S., Thomas, R. P., Ajlan, A., Pena, J., Gershon, M., Coffey, G., Kunz, P. L., Li, G., Recht, L. D.
2015; 123 (2): 277-282
- **Treatment options for optic pathway gliomas.** *Current treatment options in neurology*
Thomas, R. P., Gibbs, I. C., Xu, L. W., Recht, L.
2015; 17 (2): 333-?
- **Treatment Options for Optic Pathway Gliomas** *CURRENT TREATMENT OPTIONS IN NEUROLOGY*
Thomas, R. P., Gibbs, I. C., Xu, L. W., Recht, L.
2015; 17 (2)
- **ARE WE USING TOO MUCH BEVACIZUMAB IN OUR GBM PATIENTS?**
Ajlan, A., Thomas, P., Thomas, R., Nagpal, S., Recht, L.
OXFORD UNIV PRESS INC.2014
- **COMPLETE RESPONSE TO VEMURAFINIB IN A PATIENT WITH METASTATIC ANAPLASTIC XANTHROASTROCYTOMA**
Thomas, R., Ajlan, A., Ziskin, J., Soltys, S., Reddy, S., Recht, L., Nagpal, S.
OXFORD UNIV PRESS INC.2014
- **Simultaneous perfusion and permeability measurements using combined spin- and gradient-echo MRI.** *Journal of cerebral blood flow and metabolism*
Schmiedeskamp, H., Andre, J. B., Straka, M., Christen, T., Nagpal, S., Recht, L., Thomas, R. P., Zaharchuk, G., Bammer, R.
2013; 33 (5): 732-743
- **The incidence and significance of multiple lesions in glioblastoma** *JOURNAL OF NEURO-ONCOLOGY*
Thomas, R. P., Xu, L. W., Lober, R. M., Li, G., Nagpal, S.
2013; 112 (1): 91-97
- **Advances in the management of glioblastoma: the role of temozolomide and MGMT testing.** *Clinical pharmacology : advances and applications*
Thomas, R. P., Recht, L., Nagpal, S.
2013; 5: 1-9
- **PRELIMINARY RESULTS UTILIZING VESSEL SIZE IMAGING AS A METRIC OF RESPONSE IN GLIOBLASTOMA MULTIFORME** *17th Annual Scientific Meeting and Education Day of the Society-for-Neuro-Oncology (SNO)*
Andre, J. B., Schmiedeskamp, H., Thomas, R. P., Feroze, A., Nagpal, S., Zaharchuk, G., Straka, M., Recht, L., Bammer, R.
OXFORD UNIV PRESS INC.2012: 127–127

- **Tumor-derived chemokine MCP-1/CCL2 is sufficient for mediating tumor tropism of adoptively transferred T cells** *JOURNAL OF IMMUNOLOGY*
Brown, C. E., Vishwanath, R. P., Aguilar, B., Starr, R., Najbauer, J., Aboody, K. S., Jensen, M. C.
2007; 179 (5): 3332-3341
- **A quantitative high-throughput chemotaxis assay using bioluminescent reporter cells** *JOURNAL OF IMMUNOLOGICAL METHODS*
Vishwanath, R. P., Brown, C. E., Wagner, J. R., Meechoovet, H. B., Naranjo, A., Wright, C. L., Olivares, S., Qian, D., Cooper, L. J., Jensen, M. C.
2005; 302 (1-2): 78-89
- **Biophotonic cytotoxicity assay for high-throughput screening of cytolytic killing** *JOURNAL OF IMMUNOLOGICAL METHODS*
Brown, C. E., Wright, C. L., Naranjo, A., Vishwanath, R. P., Chang, W. C., Olivares, S., Wagner, J. R., Bruins, L., Raubitschek, A., Cooper, L. J., Jensen, M. C.
2005; 297 (1-2): 39-52
- **Quantification of chemotherapeutic target gene mRNA expression in human breast cancer biopsies: Comparison of real-time reverse transcription-PCR vs. relative quantification reverse transcription-PCR utilizing DNA sequencer analysis of PCR products** *JOURNAL OF CLINICAL LABORATORY ANALYSIS*
Juhasz, A., Frankel, P., Cheng, C., Rivera, H., Vishwanath, R., Chiu, A., Margolin, K., Yen, Y., Newman, E. M., Synold, T., Wilczynski, S., Lenz, H. J., Gandara, et al
2003; 17 (5): 184-194

PRESENTATIONS

- Daily Highlights, Society for Neuro Oncology Annual Meeting - Society for Neuro Oncology (November 17, 2018)